Floatz logo

GBM6-AD

Glioma

Jennie TaylorPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

96 Active assets in the Glioma cohort.

Asset / SponsorPhaseRating
Olutasidenib
Rigel Pharmaceuticals
Phase 4BBB
Irinotecan
Kailin Yang, MD, PhD
Phase 3B
Valproic Acid
Medical University of South Carolina
Phase 2B
DIANHYDROGALACTITOL
Kintara Therapeutics, Inc.
Phase 2B
Cyclophosphamide
Essen Biotech
Phase 2B

View all 50 →

Same molecule, other indications

GBM6-AD is also rated in:

low-grade astrocytomaDormant
CC
Indicative ·
47 / 100
View asset →
astrocytic tumorDormant
CC
Indicative ·
47 / 100
View asset →
oligoastrocytomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →